Aggregated price index with volume information
Summary:
- The momentum of the sector is very strong.
- Antibiotic Developers stocks up 3.6% on average while median return up 1.1% in a day
- Antibiotic Developers stocks up 10.6% on average while median return up 2.5% in a week
- Antibiotic Developers stocks up 14.8% on average while median return up 7.9% in a month
- When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.
Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.
- 1M winners are : Winners for past month are $SMMT 48.6%
- 1M losers are : Losers for past month are $MRK -4.7%
- 1W winners are : Winners for past week are $SMMT 31.4%
- 1W losers are : Losers for past week are $MRK -0.4%
Correlation Analysis
Index correlation analysis
Correlation for the past month is 21.2%, for the past 3 months is 16.5%
In the past month for a 5 days rolling window, the highest corrrelation is 74.3%, the lowest correlation is -26.6%, the latest correlation is 11.3%
When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.
Among pairwise correlation, the highest correlation is 42.2% between PRTK and SMMT
The lowest correlation is 1.8% between SMMT and SPRO
MIAMI & HOUSTON, July 25, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") and The University of Texas MD Anderson Cancer Center (MD Anderson) today announced a strategic five-year collaboration agreement for the purpose of accelerating the development of ivonescimab.
Applications for nanotechnology in medicine include imaging, diagnosis, or the delivery of drugs that will help medical professionals treat various diseases.
When discussing micro-cap stocks, it’s important to recognize their general overlap with the world of penny stocks. These stocks trade as shares of companies with market capitalizations between $50 million and $300 million. While those numbers may sound worthy to the individual investor, they represent a generally risky position for a handful of reasons. The first is that micro-cap stocks are often derived from young and relatively unproven companies. Just because a company publicly trades on th
MIAMI, July 03, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 330,000 shares of common stock. Awards were made to six new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company’s Compensation Committee.
CAMBRIDGE, Mass., July 03, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on May 28, 2024, the Compensation Committee of Spero’s Board of Directors approved the grant of an aggregate of 227,500 restricted stock unit awards (RSUs) to new employees under the Spero Therapeutics, I
On Monday, Merck & Co Inc (NYSE:MRK) announced the notice of the mutual exercise of an option to convert the companies’ ongoing co-development and co-commercialization agreement for opevesostat (MK-5684/ODM-208) into an exclusive global license for Merck. As previously announced under the companies’ original co-development and co-commercialization agreement, each party was granted an option to convert the co-exclusive license into an exclusive global license for Merck. Also Read: FDA Declines To
Opevesostat will now be globally developed and commercialised exclusively by MSD, with Orion set to receive milestone payments.
RAHWAY, N.J., July 01, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Orion Corporation ("Orion") today announced that notice has been provided of the mutual exercise of an option to convert the companies’ ongoing co-development and co-commercialization agreement for opevesostat (MK-5684/ODM-208), an investigational CYP11A1 inhibitor, and other candidates targeting CYP11A1 into an exclusive global license for Merck.
RAHWAY, N.J., July 01, 2024--Merck to Hold Second-Quarter 2024 Sales and Earnings Conference Call July 30
Study results are expected for two closely watched obesity drugs, while key tests await for a high-priced AbbVie acquisition and one of 2023’s largest IPOs.